Matthew Kurian, Assistant Professor of Medicine at the University of Kentucky College of Medicine, shared a post on LinkedIn:
“Excited to partner with the Innovative Healthcare Institute (IHCI) and Cincinnati Cancer Advisors for an important discussion on the implications of HER2 testing in cancer.
I’ll be highlighting the evolving role of HER2 testing in breast cancer — from HER2+ to HER2-low and ultralow, and what that means for patient care.
My colleague Dr. Ben Kuritzky, TriHealth will discuss the expanding impact of HER2 across other solid tumors, including GI, lung, and more.
Don’t miss this session bringing together perspectives across tumor types.
RSVP today to secure your spot.”
More posts featuring Matthew Kurian on OncoDaily.